IBRX270115C00004000
IBRX Jan 15 2027 4.00 Call
optionOPRA
EODOct 16, 2026
5.70USD-6.096%(-0.37)1Vol5,546OI
Loading…
Underlying
Underlying Price
$8.28
Type
Call
Strike
4
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$4.28
IBRX 4 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $6.06 | -3.35% | 1 | 54 |
| Oct 30, 2026 | 10d | $5.40 | +25.58% | 6 | 9 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 1 |
| Nov 20, 2026 | 31d | $5.45 | -12.10% | 16 | 48 |
| Nov 27, 2026 | 38d | $5.40 | -11.48% | 2 | 2 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $5.70 | -6.10% | 1 | 5,546 |
| Mar 19, 2027 | 150d | $6.49 | -3.99% | 223 | 236 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | $4.24 | +0.00% | 1 | 1 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $6.75 | -1.75% | 15 | 2,170 |
| Mar 17, 2028 | 514d | $5.25 | -9.48% | 2 | 1 |
| Jan 19, 2029 | 822d | $7.20 | +1.55% | 3 | 31 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 1 C | $9.44 | +11.06% | 10 | 222 | ITM |
| 1.5 C | $8.20 | +13.89% | 15 | 412 | ITM |
| 2 C | $8.47 | +12.93% | 20 | 1,489 | ITM |
| 2.5 C | $6.57 | -8.11% | 13 | 5,703 | ITM |
| 3 C | $7.20 | +7.30% | 200 | 11,575 | ITM |
| 3.5 C | $6.54 | -7.23% | 4 | 4,158 | ITM |
| 4 C | $5.70 | -6.10% | 1 | 5,546 | ITM |
| 4.5 C | $6.02 | +28.36% | 25 | 2,469 | ITM |
| 5 C | $4.40 | -16.98% | 41 | 26,571 | ITM |
| 5.5 C | $4.50 | -12.62% | 1 | 7,684 | ITM |
| 7.5 C | $2.65 | -11.67% | 315 | 21,168 | ITM |
| 9 C | $1.87 | -25.20% | 64 | 6,662 | OTM |
| 10 C | $1.55 | -26.19% | 2,280 | 72,472 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.